Introduction {#sec1_1}
============

Bevacizumab is thought to normalize tumor vasculature and restore the blood-brain barrier, decreasing contrast enhancement and peritumoral edema \[[@B1]\]. Conventional measurements of tumor response using MRI rely upon dimensions of enhancing tumor. Antiangiogenic treatment targeting the VEGF pathway using bevacizumab causes a rapid decrease in T1 contrast-enhancing tumor parts, with high radiographic response rates ranging between 30--60% \[[@B1]\]. However, in one third of all patients, glioblastomas are more prone to progress as nonenhancing tumor after bevacizumab treatment \[[@B2]\]. Recently defined RANO (Response Assessment in Neuro-Oncology) criteria for glioma progression recommend fluid-attenuated inversion recovery (FLAIR)/T2 hyperintensity on MRI as a surrogate for nonenhancing tumor; however, nonenhancing tumor can be difficult to differentiate from other causes of FLAIR/T2 hyperintensity (e.g., radiation-induced gliosis, peritumoral edema) \[[@B3]\]. Positron emission tomography using the radiolabeled amino acid O-(2-\[^18^F\]fluoroethyl)-L-tyrosine (^18^F-FET PET) may offer an improvement of the detection of 'true', i.e., metabolically active tumor extent of high-grade glioma over and above the information provided by contrast enhancement and FLAIR hyperintensity on MRI alone.

Case Report {#sec1_2}
===========

A 58-year-old patient suffered from aphasia and agitation 4 weeks prior to admission. Initial MRI revealed a contrast-enhancing, tumor-suspicious lesion in the left temporal lobe, and a biopsy was performed stereotactically. Histopathologic findings confirmed a glioblastoma. Molecular analysis of prognostic factors revealed that the O6-methylguanine methyltransferase promoter (MGMT) was not methylated and isocitrate dehydrogenases 1 and 2 (IDH1/IDH2) were not mutated. In order to achieve a macroscopically complete tumor resection, a fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) was performed. After surgery, fractionated external radiation therapy was initiated. Within 2 weeks after tumor resection, the aphasia improved substantially. After stratification for molecular markers, the patient was treated with concomitant radiotherapy up to a dosage of 60 Gy, and afterwards with adjuvant bevacizumab \[[@B4]\] every 2 weeks over 8 months. Due to a severe allergic reaction, the combination therapy with irinotecan had to be discontinued after the first application. During bevacizumab treatment, clinical controls and follow-up MRIs in 8- to 12-week intervals showed no signs of tumor recurrence.

After 8 months of single bevacizumab therapy, hemiparesis of the right side and deterioration of the aphasia occurred. The follow-up T1-weighted MRI (**fig. [1a](#F1){ref-type="fig"}**) demonstrates slight contrast enhancement within the left temporal lobe. In contrast, the hyperintensity on the FLAIR-weighted MRI (fig. [1b](#F1){ref-type="fig"}, encircled within black lines) is significantly larger, suggesting signs of nonenhancing tumor progression during bevacizumab treatment \[[@B2], [@B5]\]. To further evaluate the MRI results, ^18^F-FET PET (fig. [1d](#F1){ref-type="fig"}) was performed. Metabolically active tumor volume of ^18^F-FET PET uptake at a threshold =1.6 and volume of the hyperintense FLAIR signal were calculated \[[@B6], [@B7]\] (fig. [1c, e](#F1){ref-type="fig"}).

Coregistrations of ^18^F-FET PET scan (fig. [1d](#F1){ref-type="fig"}), contrast-enhanced and FLAIR-weighted MRI (fig. [1a, b](#F1){ref-type="fig"}), and volume of the FLAIR lesion (fig. [1c](#F1){ref-type="fig"}) and the metabolically active tumor (fig. [1d](#F1){ref-type="fig"}, encircled within white lines; e) show that the volume of the FLAIR hyperintensity is considerably larger than the metabolically active tumor volume. However, on superimposed images (fig. [1f](#F1){ref-type="fig"}), the volume of the FLAIR hyperintensity (grey) shows no correspondence in size and spatial configuration to the ^18^F-FET PET metabolically active tumor volume. Moreover, in comparison to the FLAIR hyperintensity, ^18^F-FET uptake at a threshold =1.6 (red) reveals additional subareas of metabolically active tumor (fig. [1f](#F1){ref-type="fig"}) in transaxial, coronal, and sagittal orientation.

For treatment of tumor recurrence, chemotherapy with dose-intensified temozolomide was initiated according to a 1 week on/1 week off regimen \[[@B8]\]. Clinically, chemotherapy response could not be observed; during follow-up an exacerbation of the aphasia and hemiparesis occurred. Due to a severe impairment of the patient\'s clinical condition, palliative care was initiated 3 months after tumor recurrence.

Discussion {#sec1_3}
==========

The differences in MRI and ^18^F-FET PET might be explained by a complex morphologic heterogeneity of glioblastoma, leading to difficult interpretation of standard MRI sequences. There are highly malignant tumor parts with and without contrast enhancement, and, furthermore, T2-based signal hyperintensity is a combination of infiltrating tumor cells, necrotic areas, tumor edema, and treatment-related leukoencephalopathy, e.g., due to radiotherapy \[[@B3]\]. In contrast, ^18^F-FET PET shows metabolically active tumor independent of any anatomic or pathophysiologic changes and may therefore reflect tumor extension more accurately than MRI \[[@B6]\]. In this context, localization of the ^18^F-FET PET metabolically active tumor does not always match the pathological findings seen on MRIs. For example, in a small group of patients with recurrent high-grade glioma treated with bevacizumab and irinotecan, which partially responded according to RANO criteria without response based on ^18^F-FET PET imaging findings, tumor progression could be detected earlier by ^18^F-FET PET \[[@B9]\].

In summary, during bevacizumab treatment, ^18^F-FET PET in addition to contrast-enhanced and FLAIR-/T2-weighted MRI might add important information for assessment of tumor recurrence, as compared with standard MRI alone.
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